A Phase 2 interventional study of Atorvastatin Oral Tablet in Mild Cognitive Impairment, sponsored by Johns Hopkins University. Recruiting at 1 site in United States. Open to participants aged 60 Years to 95 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-13.
Sponsored by Johns Hopkins University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Cognitive Dysfunction by Johns Hopkins University — 13 open to participants now, 15 under way, 1 of them phase 3. Cognitive Dysfunction · Johns Hopkins University.
Among the 34 studies in Cognitive Dysfunction by Johns Hopkins University, this one is the 25th largest by planned enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2021, is one of 6 in phase 2, reaches primary completion later than 4 of the 14 other live ones, and was the 14th registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →13 of the 34 studies in Cognitive Dysfunction by Johns Hopkins University are open now, in 1 country. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 65+ · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 60–100 · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 65+ · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 60+
Johns Hopkins University · Sites in United States
Ages 18–100
By country, each count listing its studies:
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 60 Years to 95 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 64 across 2,804 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 52 across the 33 interventional studies, 350 across the 1 observational. Of the 17 that completed or were terminated, 10 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
Johns Hopkins University is the lead sponsor of 1,817 studies on the registry; 316 are open to participants now.
Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.
7 of the studies in Cognitive Dysfunction by Johns Hopkins University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05611918Johns Hopkins UniversityREpeated ASSEssment of SurvivorS in Intracerebral Hemorrhage Study | 2026-12-31 |
| NCT07454824Johns Hopkins Universitye-ALIGN: A Patient Portal-based Intervention to Align Medications With What Matters Most | 2027-02-06 |
| NCT04123314Johns Hopkins UniversityPsilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease | 2027-06-30 |
| NCT06351540Johns Hopkins UniversityExamining the Role of Tolerance on Dose-dependent Effects of Acute THC on Oculomotor and Cognitive Performance | 2027-07-01 |
| NCT04765137Johns Hopkins UniversityEvaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI) | 2027-07-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 34 studies in Cognitive Dysfunction by Johns Hopkins University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effect of atorvastatin on brain vessel reactivity and with it on blood flow in people with mild cognitive impairment.
Participants are first being informed about potential benefits and risks of the study and are required to give written consent. After that participants will undergo detailed phone screen to determine eligibility for study entry. At week 0, participants who meet eligibility requirements will be prescribed atorvastatin (40 mg, once in the evening) in an open-label manner.
Inclusion Criteria are chosen to include participants with MCI, enriched for vascular risk factors:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive 40 mg atorvastatin orally daily in the evening.
Drug: Atorvastatin Oral Tablet
Atorvastatin pill 40 mg to be taken every night
Also known as: Lipitor oral tablet
Change of MRI whole brain cerebrovascular reactivity (wbCVR)
MRI based CVR is a newer technique that measures dilatory function of the microvessels which have been shown to be superior to measurement of Cerebral blood flow (CBF) and have also been shown to be low in participants with MCI.
Time frame: Baseline and 12 weeks
Change in plasma exosomes
Endothelial-derived exosomes (EDE) reflect the neurochemistry of cerebrovascular endothelial cells, while neuronal-enriched extracellular vesicles (nEV) are associated with brain white matter hyperintensities.
Time frame: Baseline and 12 weeks
Change in cognitive function (global neurocognitive measure)
Assessed by Global neurocognitive measure.
Time frame: Baseline and 12 weeks
Change in cognitive function (domain-specific neurocognitive measure)
Assessed by Domain-specific neurocognitive measure.
Time frame: Baseline and 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Started May 2021 (actual). Primary completion is estimated for Jul 2027, 74 months after the start.
Of 145 non-industry phase 2 interventional studies under Cognitive Dysfunction, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 64. This study's planned 74 months is above that.
Counting every sponsor, half of 187 studies reached it within 42 months; a quarter within 22 and three quarters within 62.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atorvastatin